2022
Implementation opportunities for scaling up methadone maintenance treatment in Kyrgyzstan: Methadone dosage and retention on treatment over two years
Ivasiy R, Madden LM, Farnum SO, Shumskaya N, de Leon S, Bromberg DJ, Kurmanalieva A, Duishenaliev A, Tokubaev R, Altice FL. Implementation opportunities for scaling up methadone maintenance treatment in Kyrgyzstan: Methadone dosage and retention on treatment over two years. Drug And Alcohol Dependence Reports 2022, 4: 100075. PMID: 36267100, PMCID: PMC9581459, DOI: 10.1016/j.dadr.2022.100075.Peer-Reviewed Original ResearchMethadone maintenance treatmentDosage levelsMaintenance treatmentCox multivariate regression modelMethadone dosage levelsProspective observational databaseNational treatment guidelinesProportion of patientsHigher dosage levelsOptimal dosageMMT retentionMMT patientsMethadone dosageTreatment guidelinesHIV statusMultivariate regression modelHigh doseSurvival analysisTreatment dropoutClinical settingCost-effective strategySignificant predictorsMonthsHIVObservational databaseDetermining the lower limit of detection required for HCV viral load assay for test of cure following direct‐acting antiviral‐based treatment regimens: Evidence from a global data set
Morgan JR, Marsh E, Savinkina A, Shilton S, Shadaker S, Tsertsvadze T, Kamkamidze G, Alkhazashvili M, Morgan T, Belperio P, Backus L, Doss W, Esmat G, Hassany M, Elsharkawy A, Elakel W, Mehrez M, Foster GR, Kinge C, Chew KW, Chasela CS, Sanne IM, Thanung YM, Loarec A, Aslam K, Balkan S, Easterbrook PJ, Linas BP. Determining the lower limit of detection required for HCV viral load assay for test of cure following direct‐acting antiviral‐based treatment regimens: Evidence from a global data set. Journal Of Viral Hepatitis 2022, 29: 474-486. PMID: 35278339, PMCID: PMC9248016, DOI: 10.1111/jvh.13672.Peer-Reviewed Original ResearchConceptsDetectable viraemiaDetectable HCV RNALow-level viraemiaVirological treatment failureHCV viral loadTest of cureHepatitis C virusViral load assaysHCV viraemiaHCV RNATreatment failureViral loadC virusClinical trialsMinimal fibrosisSVR12ViraemiaGlobal eliminationLogistic regressionDiagnostic performanceLevel of detectionObservational databaseIULaboratory-based assaysCure
2007
Complete Blood Cell Count as a Surrogate CD4 Cell Marker for HIV Monitoring in Resource-Limited Settings
Chen RY, Westfall AO, Hardin JM, Miller-Hardwick C, Stringer JS, Raper JL, Vermund SH, Gotuzzo E, Allison J, Saag MS. Complete Blood Cell Count as a Surrogate CD4 Cell Marker for HIV Monitoring in Resource-Limited Settings. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2007, 44: 525-530. PMID: 17259910, DOI: 10.1097/qai.0b013e318032385e.Peer-Reviewed Original ResearchConceptsBirmingham Veterans Affairs Medical CenterTotal lymphocyte countCells/microLCD4 countVeterans Affairs Medical CenterComplete blood cell countAntiretroviral treatment statusLow CD4 cellsBody mass indexBlood cell countCells/Receiver operator characteristic curveResource limited settingsObservational databaseResource-limited settingsCD4 cellsLymphocyte count
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply